drugset / Trial / NCT04638270
Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL
Phase 0
Unknown
16 enrolled
Xinqiao Hospital of Chongqing
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China · collabChongqing University Cancer Hospital · collabGracell Biotechnologies (Shanghai) Co., Ltd. · collabThe Affiliated Hospital Of Guizhou Medical University · collabThe Second Affiliated Hospital of Chongqing Medical University · collabThe Second Affiliated Hospital of Kunming Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. To make a further improvement, adapting the FasT CAR-T cells manufacture technology to shorten the manufacturing time and maintain the stemness of CAR-T cells. We launch such a clinical trial using CD19 targeted CAR-T cells for patients with relapsed and refractory B-cell NHL to evaluate the efficacy and safety of CD19 targeted CAR-T cell therapy.
Timeline
- Start
- 2020-11-21
- Primary completion
- 2021-11-01
- Completion
- 2023-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CD19 FasT CAR-T cells | Cell therapy | 300000 cells/kg | — |
| Subject | anti-CD19 FasT CAR-T cells | Cell therapy | 600000 cells/kg | — |
| Subject | anti-CD19 FasT CAR-T cells | Cell therapy | 1e+06 cells/kg | — |